An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia A

ClinicalTrials.gov · COMPLETED, 2019

108 participants

Abstract

The primary objective of the study was to evaluate the safety of rFVIIIFc (BIIB031) in previously untreated participants (PUPs) with severe hemophilia A. The secondary objectives were to evaluate the efficacy of rFVIIIFc in the prevention and treatment of bleeding episodes in PUPs, to evaluate rFVIIIFc consumption for the prevention and treatment of bleeding episodes in PUPs, and to describe experience with the use of rFVIIIFc for immune tolerance induction (ITI) in participants with inhibitors.

Conditions: Hemophilia A.

Primary outcome: Percentage of Participants With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay.

Enrollment: 108 participants.

How strong is the evidence?

Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 108 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

• ClinicalTrials.gov
• Publisher page

Related studies

• The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices Molecular & Cellular Proteomics, 2011
• The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities Proceedings of the National Academy of Sciences, 2000
• In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling British Journal of Pharmacology, 2007
• In silico prediction of splice-altering single nucleotide variants in the human genome Nucleic Acids Research, 2014
• In silico clinical trials: how computer simulation will transform the biomedical industry International Journal of Clinical Trials, 2016
• In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design Nature Communications, 2018

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free